To perform a preliminary evaluation of the clinical applicability of our set of protein markers, we carried out a limited proof-of-concept test with two biomarkers associated with TH2-derived sEVs (ITGA4 and ITGB2) and took advantage of a previous collection of serum samples from T2high and T2low asthma patients [5,20], two molecular phenotypes where TH2 cells play a differential role. The gene discussed is ITGB2; the disease is asthma.